Khalil Saleh1, Amaury Daste2, Nicolas Martin3, Elvire Pons-Tostivint4, Anne Auperin5, Ruth Gabriela Herrera-Gomez6, Neus Baste-Rotllan6, Francois Bidault7, Joel Guigay3, Christophe Le Tourneau8, Esma Saada-Bouzid9, Caroline Even6. 1. Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: khalil.saleh@gustaveroussy.fr. 2. Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, France. 3. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France. 4. Department of Drug Development and Innovation, Institute Curie, Paris, Saint-Cloud, France. 5. Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, Villejuif, France. 6. Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France. 7. Department of Radiology, Institute Gustave Roussy, Villejuif, France. 8. Department of Drug Development and Innovation, Institute Curie, Paris, Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France; Paris-Saclay University, Paris, France. 9. Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France; Université Côte d'Azur, Nice, France.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICI) are active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Recent data suggest that exposure to ICI improves response to salvage chemotherapy (SCT) in advanced non-small-cell lung cancer. We evaluated response to chemotherapy in patients who had progressed on ICI in patients with R/M SCCHN. PATIENTS AND METHODS: A retrospective study was conducted at 4 French centres. Eligibility criteria were patients who progressed after treatment with ICI for R/M SCCHN and received SCT and for whom efficacy data were available between September 2014 and January 2018. RESULTS: Of 232 patients treated with ICI, 82 met eligibility criteria: 84% were male. ICI was given as monotherapy in 45% of patients or as combination in 55%. SCT included taxanes (56.1%), cetuximab in combination with taxanes or platinum (50%), platinum-based regimen (36.6%). The median number of treatment lines before SCT was 2 (range 1-6). The objective response rate (ORR) to SCT was 30%. Three patients (4%) presented complete response and 22 patients (27%) had partial response. Median progression-free survival was 3.6 months and median overall survival was 7.8 months. The age at SCT, initial tumour location, number of prior chemotherapy regimens, type of chemotherapy before ICI, best response to ICI, site of relapse and Eastern Cooperative Oncology Group at SCT were not associated with response to SCT on univariate analysis. CONCLUSION: In R/M SCCHN, the ORR to SCT was high (30%) suggesting that exposure to ICI may increase tumour sensitivity to chemotherapy.
BACKGROUND: Immune checkpoint inhibitors (ICI) are active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Recent data suggest that exposure to ICI improves response to salvage chemotherapy (SCT) in advanced non-small-cell lung cancer. We evaluated response to chemotherapy in patients who had progressed on ICI in patients with R/M SCCHN. PATIENTS AND METHODS: A retrospective study was conducted at 4 French centres. Eligibility criteria were patients who progressed after treatment with ICI for R/M SCCHN and received SCT and for whom efficacy data were available between September 2014 and January 2018. RESULTS: Of 232 patients treated with ICI, 82 met eligibility criteria: 84% were male. ICI was given as monotherapy in 45% of patients or as combination in 55%. SCT included taxanes (56.1%), cetuximab in combination with taxanes or platinum (50%), platinum-based regimen (36.6%). The median number of treatment lines before SCT was 2 (range 1-6). The objective response rate (ORR) to SCT was 30%. Three patients (4%) presented complete response and 22 patients (27%) had partial response. Median progression-free survival was 3.6 months and median overall survival was 7.8 months. The age at SCT, initial tumour location, number of prior chemotherapy regimens, type of chemotherapy before ICI, best response to ICI, site of relapse and Eastern Cooperative Oncology Group at SCT were not associated with response to SCT on univariate analysis. CONCLUSION: In R/M SCCHN, the ORR to SCT was high (30%) suggesting that exposure to ICI may increase tumour sensitivity to chemotherapy.
Authors: N N Alrabadi; H M Abushukair; O E Ababneh; S S Syaj; S S Al-Horani; A A Qarqash; O A Darabseh; M M Al-Sous; S R Al-Aomar; Y B Ahmed; R Haddad; F A Al Qarqaz Journal: Clin Transl Oncol Date: 2021-04-20 Impact factor: 3.405